Introduction: The purpose of this article is to determine the prevalence of ONJ in patients who have undergone intravenous bisphosphonate therapy, and relate the risk factors described (including Actinomices); indeed, to establish a protocol to reduce the risk of developing ONJ and to evaluate the evolution of the patient according to the sample’s antibiogram
The antiresorptive drugs bisphosphonates and denosumab arewidely used to preserve bone strength by i...
Copyright © 2014 V. Aftimos et al. This is an open access article distributed under the Creative Com...
Chemotherapy-associated osteonecrosis of the jaw caused by bisphosphonates is an exposure of necroti...
Background: Osteonecrosis of the jaw (ONJ) is a destructive bone process in patients undergoing bisp...
Osteonecrosis of the jaw is a very severe complication in patients using antiresorptive drugs, which...
There is evidence that the use oral bisphosphonates can lead to osteronecrosis of the jaws (ONJ). Al...
There is evidence that the use oral bisphosphonates can lead to osteronecrosis of the jaws (ONJ). Al...
Background: Bisphosphonates (BPs) and other antiresorptive agents such as denosumab are widely presc...
Objective There is strong evidence of a link between the use of systemic bisphosphonates (BPs) and o...
Osteonecrosis of the jaws (ONJ) is an adverse side event of bisphosphonates and denosumab, antiresor...
PURPOSE: The aim of this study was to investigate the incidence of bisphosphonate-related osteonecro...
© 2012 Dr. Claudine Elizabeth TsaoAnti-resorptive drugs, including bisphosphonates, reduce bone turn...
OBJECTIVE: This literature review was performed to elucidate the relationship between bisphosphonate...
The literature describes an increasing presence of bisphosphonate-induced osteonecrosis of the jaws ...
Although the evidence available associating bisphosphonates (BP) with osteonecrosis of the jaw (ONJ)...
The antiresorptive drugs bisphosphonates and denosumab arewidely used to preserve bone strength by i...
Copyright © 2014 V. Aftimos et al. This is an open access article distributed under the Creative Com...
Chemotherapy-associated osteonecrosis of the jaw caused by bisphosphonates is an exposure of necroti...
Background: Osteonecrosis of the jaw (ONJ) is a destructive bone process in patients undergoing bisp...
Osteonecrosis of the jaw is a very severe complication in patients using antiresorptive drugs, which...
There is evidence that the use oral bisphosphonates can lead to osteronecrosis of the jaws (ONJ). Al...
There is evidence that the use oral bisphosphonates can lead to osteronecrosis of the jaws (ONJ). Al...
Background: Bisphosphonates (BPs) and other antiresorptive agents such as denosumab are widely presc...
Objective There is strong evidence of a link between the use of systemic bisphosphonates (BPs) and o...
Osteonecrosis of the jaws (ONJ) is an adverse side event of bisphosphonates and denosumab, antiresor...
PURPOSE: The aim of this study was to investigate the incidence of bisphosphonate-related osteonecro...
© 2012 Dr. Claudine Elizabeth TsaoAnti-resorptive drugs, including bisphosphonates, reduce bone turn...
OBJECTIVE: This literature review was performed to elucidate the relationship between bisphosphonate...
The literature describes an increasing presence of bisphosphonate-induced osteonecrosis of the jaws ...
Although the evidence available associating bisphosphonates (BP) with osteonecrosis of the jaw (ONJ)...
The antiresorptive drugs bisphosphonates and denosumab arewidely used to preserve bone strength by i...
Copyright © 2014 V. Aftimos et al. This is an open access article distributed under the Creative Com...
Chemotherapy-associated osteonecrosis of the jaw caused by bisphosphonates is an exposure of necroti...